Extended-Release Naltrexone Improves Viral Suppression among Incarcerated
Persons Living with HIV with
Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind,
Placebo-Controlled Randomized Trial.
Springer SA, Di Paola A, Azar M,
J Acquir Immune Defic Syndr.
2018 Jan 23.
Abstract
Extended-release naltrexone opioid
treatment at jail re-entry (XOR).
McDonald RD, Tofighi B, Laska E, et al
Contemp Clin Trials. 2016 May 10.
Abstract
Feasibility, acceptability and tolerability of
targeted naltrexone for non-dependent methamphetamine-using and
binge-drinking men who have sex with men.
Santos GM, Coffin P, Santos D, et al
J Acquir Immune Defic Syndr.
2015 Dec 15
Abstract
Treating Opioid Dependence With Injectable
Extended-Release Naltrexone (XR-NTX): Who Will Respond?
Nunes EV, Krupitsky E, Ling W, et al
J Addict Med. 2015
Apr 21.
Abstract
Employment-Based Reinforcement of Adherence to Oral
Naltrexone in Unemployed Injection Drug Users:
12-Month Outcomes.
Dunn K, DeFulio A, Everly JJ, et al
Psychol Addict Behav.
2014 Aug 18.
Abstract
Injectable and implantable sustained release naltrexone in the
treatment of opioid addiction
Kunĝe N, Lobmaier P, Ngo H, Hulse GK
Br
J Clin Pharmacol. 2012 Oct 22.
Abstract
Hepatic Safety and Antiretroviral Effectiveness in
HIV-Infected Patients Receiving Naltrexone.
Tetrault JM, Tate JP, McGinnis KA, et al
Alcohol Clin Exp Res.
2011 Jul 28.
Abstract
Use of Naltrexone to Treat Opioid Addiction in a
Country in Which Methadone and
Buprenorphine Are Not Available.
Krupitsky E, Zvartau E, Woody G.
Curr Psychiatry Rep.
2010 Jul 17
Abstract
|
Opiate Mgmt Main Page
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
